Editas Medicine Announces Strategic Updates and Portfolio

Editas Medicine Announces Strategic Updates and Portfolio ...

Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced a strategic update, including portfolio reprioritization and ...

Editas Medicine Announces Progress Towards 2024 Goals ...

Editas Medicine Announces Progress Towards 2024 Goals, Including Achievement of In Vivo Preclinical Proof of Concept and Strategic Update.

Editas Medicine Announces Strategic Updates and Portfolio

As a clinical stage genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/ ...

Editas Medicine and Genevant Sciences to Collaborate to Develop ...

... portfolio, today announced that they have entered into a collaboration and nonexclusive license agreement to combine Editas Medicine's ...

Search - Editas Medicine

... EDIT-301 for the Treatment of Severe Sickle Cell Disease · News · Editas ... Editas Medicine Announces Strategic Updates and Portfolio Reprioritization ...

Semi Trotto on LinkedIn: Editas Medicine Announces Strategic ...

Editas Medicine Announces Strategic Updates and Portfolio Reprioritization | Editas Medicine.

Search - Editas Medicine

... EDIT-301 for the Treatment of Severe Sickle Cell Disease · SEC Filings · Form 8 ... Editas Medicine Announces Strategic Updates and Portfolio Reprioritization ...

CRISPR Investors on X: "Editas Medicine Announces Strategic ...

Editas Medicine Announces Strategic Updates and Portfolio Reprioritization https://t.co/V2bKQkEVob.

Editas Medicine - BioSpace

Editas Medicine Announces Third Quarter 2024 Results and Business Updates ... Editas Medicine to Host Strategic Update Webinar to Detail Progress Towards ...

Editas Medicine Announces Fourth Quarter and Full Year 2023 ...

We also created value for Editas through business development, leveraging our strong IP portfolio via sublicenses to other pharmaceutical and ...

Editas Medicine Highlights 2024 Anticipated Milestones and ...

Anticipated 2024 milestones include: present reni-cel clinical data updates mid-year and year-end, initiate the RUBY clinical trial ...

Press Release Distribution and Management - GlobeNewswire

Editas-Logo-Small (1).jpg. Editas Medicine Announces Strategic Updates and Portfolio Reprioritization. January 09, 2023 08:15 ET | Source: Editas Medicine, Inc.

Media Center - Thirdrockventures

Third Rock News. January 11, 2021. Editas Medicine. Editas Medicine Announces Transition Of Chief Scientific Officer. Read press release. January 11, 2021.

EDIT - Editas Medicine, Inc. Latest Stock News & Market Updates

Editas Medicine (Nasdaq: EDIT), a clinical-stage gene editing company, has announced a strategic update webinar scheduled for Tuesday, October 22, 2024, at 8:00 ...

Editas Medicine changes strategy for lead CRISPR program

Sign up to receive email updates. Join industry leaders for a daily roundup of biotech & pharma news. Today's issue. Gilead's Livdelzi reduced ...

Research and Pipeline - Editas Medicine

We are researching and developing two types of gene editing medicines: in vivo gene editing medicines that edit genes inside the body, and ex vivo gene editing ...

Company Announcement - Markets data - Financial Times

Editas Medicine to Host Strategic Update Webinar to Detail Progress Towards 2024 Goals, Including Achievement of Establishing In Vivo ...

Editas Medicine Announces Fourth Quarter and Full Year 2020 ...

Editas Medicine Announces Fourth Quarter and Full Year 2020 Results and Update ... portfolio of in vivo gene edited medicines and ex vivo gene edited cell ...

Editas Medicine Announces Third Quarter 2024 Results And ...

... Strategic Update Webinar on October 22, 2024. A replay of the webinar is available in the Investors section of the Editas Medicine website ...

Editas Medicine, Inc. (EDIT) Strategic Update Call Transcript

Editas Medicine, Inc. (NASDAQ:EDIT) Strategic Update Conference Call October 22, 2024 8:00 AM ETCompany ParticipantsCristi Barnett ...